Interaction of ?2-glycoprotein I with members of the lo family

Journal of Thrombosis and Haemostasis

4, 1680-1690

DOI: 10.1111/j.1538-7836.2006.02036.x

Citation Report

#	Article	IF	Citations
1	In search for a receptor for antiphospholipid antibodies on target cells. Journal of Thrombosis and Haemostasis, 2006, 4, 1678-1679.	3.8	3
2	The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood, 2007, 109, 1507-1514.	1.4	78
3	â€œResurrection of thrombinâ€•in the pathophysiology of the antiphospholipid syndrome. Arthritis and Rheumatism, 2007, 56, 393-394.	6.7	6
4	Survey of the year 2006 commercial optical biosensor literature. Journal of Molecular Recognition, 2007, 20, 300-366.	2.1	108
5	Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. British Journal of Haematology, 2007, 139, 113-120.	2.5	23
6	Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the lowâ€density lipoprotein receptor family. Journal of Neurochemistry, 2008, 104, 21-37.	3.9	71
7	Platelets express three different splice variants of ApoER2 that are all involved in signaling. Journal of Thrombosis and Haemostasis, 2007, 5, 1538-1544.	3.8	43
8	Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Reviews, 2008, 22, 93-105.	5.7	74
9	The antiphospholipid syndrome and heart valve surgery. European Journal of Cardio-thoracic Surgery, 2008, 33, 168-181.	1.4	71
10	Platelets and the antiphospholipid syndrome. Lupus, 2008, 17, 888-894.	1.6	47
11	Tissue factor in the antiphospholipid syndrome. Lupus, 2008, 17, 953-959.	1.6	37
12	Pathogenic role of antiphospholipid antibodies. Lupus, 2008, 17, 405-411.	1.6	84
13	Î²2-glycoprotein I and annexin A5 phospholipid interactions: Artificial and cell membranes. Autoimmunity Reviews, 2009, 9, 5-10.	5.8	22
14	Structural insights into recognition of Î²2â€glycoprotein I by the lipoprotein receptors. Proteins: Structure, Function and Bioinformatics, 2009, 77, 940-949.	2.6	9
15	Mode of Interaction between Î²2GPI and Lipoprotein Receptors Suggests Mutually Exclusive Binding of Î²2GPI to the Receptors and Anionic Phospholipids. Structure, 2010, 18, 366-376.	3.3	27
16	Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B. Journal of Medical Virology, 2010, 82, 224-331.	5.0	13
17	Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus, 2010, 19, 370-378.	1.6	44
18	The role of LRP8 (ApoER2â€™) in the pathophysiology of the antiphospholipid syndrome. Lupus, 2010, 19, 389-393.	1.6	18

#	Article	IF	Citations
19	TLR2 Is One of the Endothelial Receptors for Î²2-Glycoprotein I. Journal of Immunology, 2010, 185, 1550-1557.	0.8	71
20	New insights into the molecular basis of the antiphospholipid syndrome. Drug Discovery Today Disease Mechanisms, 2011, 8, e47-e52.	0.8	16
21	Mechanisms of anti-phospholipid antibody formation and action. Thrombosis Research, 2011, 127, S40-S42.	1.7	21
23	Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood, 2011, 117, 1408-1414.	1.4	109
24	Î²2-Glycoprotein I: a novel component of innate immunity. Blood, 2011, 117, 6939-6947.	1.4	101
25	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine, 2011, 270, 110-122.	6.0	91
26	Î²2â€GlycoproteinÂI: evolution, structure and function. Journal of Thrombosis and Haemostasis, 2011, 9, 1275-1284.	3.8	180
27	Plasma gelsolin facilitates interaction between Î²₂ glycoprotein I and Î±₅Î²₁ integrin. Journal of Cellular and Molecular Medicine, 2011, 15, 141-151.	3.6	25
28	Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. Blood, 2012, 120, 4134-4142.	1.4	6
29	Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. European Journal of Clinical Investigation, 2012, 42, 1126-1135.	3.4	36
30	Antiâ€Î²₂â€glycoprotein I antibodies. Annals of the New York Academy of Sciences, 2013, 1285, 44-58.	3.8	29
31	Receptors involved in cell activation by antiphospholipid antibodies. Thrombosis Research, 2013, 132, 408-413.	1.7	32
32	Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. Journal of Autoimmunity, 2013, 47, 45-57.	6.5	64
33	Inhibition of Nitric Oxide and Antiphospholipid Antibody-Mediated Thrombosis. Current Rheumatology Reports, 2013, 15, 324.	4.7	33
34	The involvement of CD36 in monocyte activation by antiphospholipid antibodies. Lupus, 2013, 22, 761-771.	1.6	11
35	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology, 2013, 52, 1775-1784.	1.9	25
36	Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1395-1405.	3.8	28
37	Inhibition of thrombotic properties of persistent autoimmune anti-Î²2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood, 2014, 123, 1090-1097.	1.4	35

#	Article	IF	Citations
38	The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome. Current Rheumatology Reports, 2015, 17, 14.	4.7	61
39	An A1â€“A1 mutant with improved binding and inhibition of Î²2<scp>GPI</scp>/antibody complexes in antiphospholipid syndrome. FEBS Journal, 2015, 282, 864-873.	4.7	7
40	Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Human Reproduction Update, 2015, 21, 97-118.	10.8	86
41	Recent advances in understanding antiphospholipid syndrome. F1000Research, 2016, 5, 2908.	1.6	12
42	Soluble analog of ApoER2 targeting beta2â€glycoprotein I in immune complexes counteracts hypertension in lupusâ€prone mice with spontaneous antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2016, 14, 1298-1307.	3.8	5
43	Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein Beta 2-Glycoprotein I. Scientific Reports, 2016, 6, 33656.	3.3	18
44	Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-Î²2 glycoprotein I antibodies. Lupus, 2016, 25, 1288-1298.	1.6	7
45	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity. , 2017, , 117-143.		3
47	New Insights in the Pathophysiology of Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 475-482.	2.7	26
48	The Lupus Anticoagulant Paradox. Seminars in Thrombosis and Hemostasis, 2018, 44, 445-452.	2.7	33
49	Anti-Î²2GPI/Î²2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology, 2018, 138, 140-150.	4.1	36
50	Mechanisms of Antiphospholipid Syndrome Induction: Role of NKT Cells. Biochemistry (Moscow), 2019, 84, 992-1007.	1.5	0
52	Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2021, 47, 787-799.	2.7	2
53	Antiphospholipid antibodies promote leukocyteâ€“endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via Î²2GPI and apoER2. Journal of Clinical Investigation, 2011, 121, 120-131.	8.2	165
54	A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid Syndrome. PLoS ONE, 2010, 5, e15345.	2.5	27
55	Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus. PLoS ONE, 2015, 10, e0140900.	2.5	10
57	What are the Target Cells and Receptors that are Recognized by Antiphospholipid Antibodies?. , 2012, , 103-113.		1
59	Structural Changes in Î²2-Glycoprotein I and the Antiphospholipid Syndrome. , 0, , .		0

#	Article	IF	Citations
60	Digital Image Processing Assessment of the Differential in vitro Antiangiogenic Effects of Dimeric and Monomeric Beta2-Glycoprotein I. Journal of Cytology & Histology, 2013, 04, .	0.1	0
62	Natural Proteins Involved in Antiphospholipid Syndrome. , 2017, , 15-27.		1
63	Practical approaches to laboratory assessment of risk of reÑ€urent thrombosis in antiphospholipid syndrome. Medical Alphabet, 2020, 4, 16-22.	0.2	1
64	Pathophysiology of Antiphospholipid Syndrome. Thrombosis and Haemostasis, 2022, 122, 1085-1095.	3.4	7
65	Alcohol-dependent downregulation of apolipoprotein H exacerbates fatty liver and gut microbiota dysbiosis in mice. Lipids in Health and Disease, 2022, 21, .	3.0	3
66	Antiphospholipid antibodies in autoimmune thyroid diseases. Journal of Clinical Laboratory Analysis, 2022, 36, .	2.1	3
67	Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. IScience, 2023, 26, 106100.	4.1	0
68	Identification of Key Modules and Hub Genes Involved in Regulating the Color of Chicken Breast Meat Using WGCNA. Animals, 2023, 13, 2356.	2.3	1
69	Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis. Journal of Lipid Research, 2023, , 100483.	4.2	0
70	Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome. Critical Reviews in Clinical Laboratory Sciences, 0, , 1-18.	6.1	0